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APlasmodium falciparum circumsporozoite protein (CSP)-based recombinant fusion vaccine is the firstmalaria vaccine to reach
phase III clinical trials. Resistance to infection correlatedwith the production of antibodies to the immunodominant central repeat
region of the CSP. In contrast toP. falciparum, vaccine development against the CSP ofPlasmodium vivaxmalaria is far behind. Based
on this gap in our knowledge, we generated a recombinant chimeric protein containing the immunodominant central repeat regions of
theP. vivaxCSP fused to Salmonella enterica serovar Typhimurium-derived flagellin (FliC) to activate the innate immune system. The
recombinant proteins that were generated contained repeat regions derived from each of the 3 different allelic variants of theP. vivax
CSPor a fusion of regions derived fromeach of the 3 allelic forms.Micewere subcutaneously immunizedwith the fusion proteins
alone or in combinationwith the Toll-like receptor 3 (TLR-3) agonist poly(I·C), and the anti-CSP serum IgG responsewasmeasured.
Immunizationwith amixture of the 3 recombinant proteins, each containing immunodominant epitopes derived froma single allelic
variant, rather than a single recombinant protein carrying a fusion of regions derived fromeach of 3 allelic forms elicited a stronger
immune response. This responsewas independent of TLR-4 but requiredTLR-5/MyD88 activation. Antibody titers significantly in-
creasedwhenpoly(I·C)was used as an adjuvantwith amixture of the 3 recombinant proteins. These recombinant fusion proteins are
novel candidates for the development of an effectivemalaria vaccine againstP. vivax.
For the past 20 years, a Plasmodium falciparum circumsporozo-ite protein (CSP)-based recombinantmalaria vaccine has been
at the forefront of malaria vaccine research (reviewed in reference
1). This vaccine comprises a recombinant fusion protein of the
C-terminal portion of the P. falciparum CSP (RT) and the hepa-
titis B surface antigen (S). The fusion protein (RTS) when ex-
pressed together with the hepatitis B antigen (S) in Saccharomyces
cerevisiae naturally assembles into a virus-like particle termed
RTS,S. This particle is part of the vaccine formulation RTS,S/
AS01E that also includes monophosphoryl lipid A and QS21 in a
liposomal suspension (1).
This vaccine formulation is the first of the malaria vaccines to
reach phase III clinical trials. The vaccination efficiency, which
was measured for 14 months after the administration of the first
dose, was 50.4%, and it was determined by examining the retar-
dation of the first clinical malaria episode in 5- to 17-month-old
African children (2). A parallel study in 6- to 12-week-old infants
vaccinated with RTS,S/AS01E revealed a vaccine efficacy of 30.1%
(3). In spite of the initial success in the 5- to 17-month-old chil-
dren, the efficacy of RTS,S/AS01E declined to 16.8% over a 4-year
period (4).
An examination of the mechanism of vaccine action revealed
that an increase in anti-CSP antibody titers correlated with pro-
tection against clinicalmalaria episodes (5). This field observation
is in agreement with the results obtained from the phase IIb clin-
ical trials in adults, which showed that anti-CSP antibodies played
a prominent role in conferring resistance tomalaria challenge (6).
These putative protective antibodies mainly target the immuno-
dominant repeat region of the P. falciparum CSP (6).
There still remains a tremendous need to develop newmalaria
vaccine candidates, especially those targeting Plasmodium vivax,
the second-most-prevalent cause of malaria worldwide (7). On
the basis of the results obtained with the P. falciparum CSP-de-
rived vaccine, we generated recombinant polypeptides containing
various immunodominant regions of the P. vivax CSP fused with
a strong agonist of the innate immune system, the flagellin (FliC)
protein of Salmonella enterica serovar Typhimurium. The en-
hanced immunogenicity of FliC-containing fusion proteins has
been previously demonstrated in studies of P. vivax and P. falcip-
arummerozoite-derived vaccines (8–10).
In contrast to the P. falciparumCSP, 3 different allelic forms of
the P. vivaxCSP have been identified to date. The 2most common
alleles are VK210 and VK247 (11, 12). A third allelic form (called
P. vivax-like) may exist but is still a matter of debate. Several re-
ports have described the existence of this allelic form in different
parts of the world (13–16). However, one study that analyzed 126
samples from P. vivax-infected individuals fromCentral America,
South America, Africa, southeast Asia, and India failed to detect
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this allelic form of the CSP (17). The variations between the allelic
forms mainly occur in the central immunodominant repeat re-
gion. Distinct nonapeptides have been identified for each of the
allelic forms, GDRA(D/A)GQPA in the VK210 CSP, ANGA(G/
D)(N/D)QPG in the VK247 CSP, and APGANQ(E/G)GAA in the
P. vivax-like CSP. The existence of 3 allelic forms requires a vac-
cine to elicit antibodies against all 3 immunodominant epitopes of
the P. vivax CSP in order to have universal coverage. To achieve
this, 2 approaches were used in this study. The first approach
involved mixing 3 recombinant fusion proteins, each of which
expressed 1 of the 3 allelic forms. Alternatively, a single recombi-
nant fusion protein that contained representative epitopes from
the 3 allelic forms (All-CS-epitopes) was generated. The immuno-
genicity of the recombinant fusion proteins was assessed by im-
munizing mice with the recombinant proteins individually, the
mixture of the 3 allelic forms, or the protein containing a fusion of
all 3 immunodominant epitopes (All-CS-epitopes). The serum
IgG immune response was compared following the immunization
of mice with each of the different preparations, given alone or in
combination with an adjuvant, the TLR-3 agonist poly(I·C).
MATERIALS AND METHODS
Ethics statement. This study was carried out in strict accordance with the
recommendations provided by the Guide for the Care and Use of Labo-
ratory Animals of the Brazilian National Council of Animal Experimen-
tation (http://www.cobea.org.br/). The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Institutional An-
imal Care and Use Committee at the Federal University of São Paulo (no.
CEP 0426/09).
Mice. Wild-type (WT) female 6- to 8-week-old C57BL/6 (H2b) mice
and age- and sex-matched TLR-4, TLR-5, orMyD88 knockout (KO) (18–
20)micewere purchased from theCenter forDevelopment of Experimen-
tal Models (CEDEME), Federal University of São Paulo, Brazil.
Generation of recombinant fusion proteins. Details on the genera-
tion of theHis-FliC-VK210 fusion protein have been previously described
(21). To generate the other recombinant fusion proteins, we followed the
same strategy, using the following recombinant gene sequences: for
VK247, 5=-CAAGCTTGCGCCAGCGATATGGCGAAAAAAGAAACC
GTGTGGCGTCTGGAAGAATTTGGCCGCTTCGCAAACGGTGCAG
GTAATCAGCCGGGTGCCAATGGCGCCGGTAATCAGCCGGGTGC
GAATGGCGCGGGTAATCAGCCGGGTGCTAATGGCGCTGGTAAT
CAGCCGGGTGCAAATGGCGCAGGCAACCAGCCGGGTGCCAATG
GTGCCGGCAATCAGCCGGGTGCCAACGGCGCAGGCAATCAACC
GGGTGCCAATGGCGCAGGCAATCAGCCGGGTTAACTCGAG-3=;
for P. vivax-like, 5=-CAAGCTTGCGCCAGCGATATGGCGAAAAAAG
AAACCGTGTGGCGTCTGGAAGAATTTGGCCGCTTCGCACCGGG
TGCGAACCAGGAAGGCGGTGCAGCAGCACCGGGTGCGAATCAG
GAAGGCGGTGCGGCCGCACCGGGTGCCAATCAAGAAGGCGGTG
CCGCCGCACCGGGTGCAAATCAAGAAGGCGGTGCGGCAGCCCC
GGGCGCCAATCAGGAAGGCGGTGCCGCCGCCCCGGGTGCTAAC
CAAGAAGGCGGTGCTGCGGCCCCGGGCGCCAACCAAGAAGGCG
GTGCCGCGGCCCCGGGCGCTAACCAGGAAGGCGGTGCCGCGTA
ACTCGAG-3=; and for All-CS-epitopes, 5=-CAAGCTTGCGCAAGCGA
TATGGCGAAAAAAGAAACCGTGTGGCGTCTGGAAGAATTTGGCC
GTTTCGATCGTGCAGATGGTCAGCCGGCAGGTGACCGCGCCGA
CGGTCAGCCGGCAGGTGATCGTGCAGCCGGTCAGCCGGCCGGT
GATCGTGCAGCGGGCCAGCCGGCGGGTGATCGCGCCGATGGTC
AACCGGCGGGTGATGCAAACGGTGCAGGTAATCAGCCGGGCGC
CAATGGCGCAGGTAATCAGCCGGGTGCCAATGGTGCCGGCAAT
CAGCCGGGCGCCAACGGCGCCGGTAATCAGCCGGGTGCACCGG
GTGCAAACCAGGAAGGCGGTGCAGCAGCACCGGGTGCAAATCA
AGAAGGCGGTGCCGCAGCCCCGGGCGCCAATCAAGAAGGCGGT
GCGGCCGCCCCGGGTGCAAATCAGGAAGGCGGTGCCGCCTAA
CTCGAG-3=. The regions in bold type represent the target sites for
HindIII andXhoI. The recombinant proteinwas expressed andpurified as
previously described (8, 21). Protein concentrations were determined by
the Bradford assay and SDS-PAGE analysis.
FliC purification.Native Salmonella Typhimurium FliC was purified
from the attenuated Salmonella Typhimurium SL3201 strain, which ex-
presses FliC but not FljB (8). The purity of the preparationswas verified by
SDS-PAGE.
Immunization regimen.Mice were subcutaneously (s.c.) immunized
thrice with 1 or 10 g of the fusion protein or the purified FliC, with
immunizations being administered 3 weeks apart. In the first immuniza-
tion, a final volume of 50l was injected into each hind footpad, while for
the second and third immunizations, a final volume of 100l was injected
at the base of the tail. In some experiments, the recombinant fusion pro-
teins were administered with an adjuvant. The TLR-3 agonist poly(I·C)
(50 g/dose/mouse) (InvivoGen, San Diego, CA) or complete (CFA) or
incomplete (IFA) Freund’s adjuvant (Sigma-Aldrich Co., St. Louis, MO),
administered as an emulsion (1:1 [vol/vol]) with the immunogen, were
used.
Immunological assays. Serum anti-P. vivax CSP (PvCSP) antibodies
were detected by enzyme-linked immunosorbent assay (ELISA) as de-
scribed previously (8, 21). Briefly, the recombinant proteins hexahistidine
(His6)-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-P. vivax-
like (100 to 400 ng/well) were employed as capture agents. A detailed
description of these proteins, which contain the entire PvCSP protein,
including the N- and C-terminal portions and the repeats (VK210,
VK247, orP. vivax-like), will be published elsewhere. Serum samples from
immunized and nonimmunized mice were tested at serial dilutions from
1:200 to 1:819,200. A peroxidase-conjugated goat anti-mouse IgG
(Sigma-Aldrich Co.) was used as the detection antibody at a final dilution
of 1:1,000. The highest dilution yielding an optical density at 492 nm
(OD492) of 0.1 was considered the anti-PvCSP antibody titer. We per-
formed, in parallel, a standard curve of purifiedmouse IgG (Sigma) using
the capture anti-Fab (fragment, antigen binding) antibody (Sigma) ac-
cording to the protocol suggested in reference 22. According to our stan-
dard curve of mouse IgG titers, antibody titers of 104 represent5g/ml
of specific IgG. The results are presented as means the standard devia-
tion (SD).
Statistical analyses.One-way analysis of variance (ANOVA), the Stu-
dent t test, the Tukey honestly significant difference (HSD) test, and the
Kruskal-Wallis one-way analysis of variance were used to compare the
differences between the mean values of the antibody titers in the immu-
nization groups. Differences were considered significant when the P value
was0.05.
RESULTS
Recombinant flagellin fusion proteins.Wegenerated 3 recombi-
nant fusion proteins containing a hexahistidine tag (His6) and the
allelic variants of the CSP immunodominant regions (VK210,
VK247, or P. vivax-like) fused to the C-terminal end of FliC. In
addition, we generated a fourth recombinant protein expressing
all 3CSP immunodominant regions as a fusion polypeptide linked
to theC-terminal end of FliC (schematically represented in Fig. 1).
This recombinant protein contained fewer repeats of each allelic
form of the CSP due to the constraint of the number of amino
acids that we can add to the C-terminal region. We observed that
recombinant proteins with larger amino acid insertions were not
stable (M. T. A. Leal and M. M. Rodrigues, unpublished data).
Under denaturing (reducing) conditions, the purified proteins
yielded 2 bands, a predominant band of 60 to 70 kDa and a
larger band of 130 kDa (Fig. 2A). The recombinant protein in
the bands was identified using a monoclonal antibody (MAb) to
the His6 tag (Fig. 2B). The larger band most likely represents a
dimer of the recombinant protein, which remains in this form
even under denaturing conditions.
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In previous studies, we determined that the fusion polypeptide
His6-FliC-VK210 retained the ability to be recognized by MAb
(2F2) specific for the immunodominant VK210 epitope (21, 23).
ELISA and an immunoblot assay performed with MAb (2F2)
showed that this epitope is available for immune recognition in
the fusion protein His6-FliC-All-CS-epitope (data not shown).
The anti-Vk247MAb (2E10.E9) (A. Cochrane, unpublished data)
recognized the His6-FliC-VK247 and His6-FliC-All-CS-epitope
recombinant proteins (Fig. 2C).
CSP-specific antibody responses in mice immunized with
the recombinant fusion proteins. The anti-CSP serum IgG re-
sponse was determined in 6 groups of C57BL/6 mice immunized
with either the purified fusion proteins or native FliC. Eachmouse
received 10g of protein per immunization, in the absence of any
adjuvants. The vaccination timeline is depicted in Fig. 3A.
Mice immunized with the recombinant proteins His6-FliC-
VK210 (G2), His6-FliC-VK247 (G3), or His6-FliC-P. vivax-like
(G4) developed significant anti-PvCSP IgG titers, with the anti-
bodies recognizing the homologous allelic forms (Fig. 3B, C, and
D). After 2 or 3 immunizations, the antibody titers to the CSP
allelic variants VK210 and VK247 were in the range of 104 (equiv-
alent to 5g/ml of specific IgG). In contrast, the antibody titers to
the P. vivax-like CSP allelic form were significantly higher (in the
range of 105) (Fig. 3D).
The sera of mice immunized with the individual proteins (G2,
G3, and G4) were tested for the presence of cross-reactive anti-
bodies using the His6-PvCSP-VK210, His6-PvCSP-VK247, or
His6-PvCSP-P. vivax-like protein on the plates. We found that
mice immunized with His6-FliC-VK247 (G3) or His6-FliC-P.
vivax-like (G4) developed cross-reactive anti-PvCSP IgG titers to
His6-PvCSP-VK210. However, these titers were significantly
lower than those of mice immunized with G2 (P  0.01 in both
cases, data not shown). In addition, mice immunized with His6-
FliC-VK210 (G2) or His6-FliC-P. vivax-like (G4) developed neg-
ligible IgG titers to His6-PvCSP-VK247 (data not shown). Finally,
mice immunized with His6-FliC-VK210 (G2) or His6-FliC-
VK247 (G3) failed to generate IgG titers to the His6-PvCS-P.
vivax-like protein (data not shown).We concluded that the cross-
reactive IgG antibodies are very limited and it is not possible to use
a single variant as a universal vaccine.
Mice immunized with the mixture of His6-FliC-VK210, His6-
FliC-VK247, and His6-FliC-P. vivax-like (G5) proteins produced
immune responses targeting all 3 allelic forms. The immune re-
sponse inmice injected with this mixture was as high as or slightly
lower than (Fig. 3B, C, andD) that inmice receiving single-fusion-
protein immunizations. In one case only (VK210), there was a
statistically significant difference between groups 2 and 5 (P 
0.05, one-way ANOVA). In contrast, mice immunized with the
recombinant fusion protein His6-FliC-All-CS-epitopes (G6)
failed to generate a significant antibody response to the VK210 or
VK247 CSP variants (Fig. 3B and C). Hence, we concluded that
immunization with a mixture of the 3 different allelic forms is the
most suitable strategy to elicit an effective immune response.
To understand the nature of the humoral immune response,
we examined the subclass distribution of IgG anti-CSP response in
mice from groups 2, 3, and 4. All mice immunized with the re-
combinant fusion proteins developed higher IgG1 levels, with
IgG1/IgG2c ratios ranging from 10.66 to 512 (Fig. 4).
The PvCSP-specific antibody response in mice immunized
withHis6-FliC-PvCS-VK210 isdependentonTLR-5andMyD88
activation. The innate immune agonist FliC activates different
pattern recognition receptors (24–26). In our study, we investi-
gated the activation of TLR-4, TLR-5, andMyD88 by immunizing
wild-type (WT), as well as TLR-4, TLR-5, and MyD88 KO mice
with His6-FliC-VK210.We estimated the serum antibody titers in
these animals after each immunization. The antibody titers in
TLR-5 or MyD88 KO mice were significantly lower than those
in WT mice (Fig. 5). In contrast, TLR-4 KO mice mounted a
humoral immune response similar to that observed in WT mice.
These results demonstrated that TLR-5 and MyD88 but not
TLR-4 signaling were required for the immunogenicity of the re-
combinant fusion proteins. In addition to the antibody titers, we
estimated the IgG1/IgG2c ratio in these animals.We found that in
WT, TLR-5, MyD88, or TLR-4-KO mice, the ratios were 217.6,
38.4, 65.6, and 64, respectively (data not shown).
Use of poly(I·C) as an adjuvant improved antibody response
to the admixed proteins. To increase the antibody titers to all 3
allelic variants of CSP, we employed new vaccine formulations
that contained a mixture of the recombinant fusion protein and a
FIG 2 SDS-PAGE of the recombinant proteins. (A) Each lane was loaded with
approximately 1 g of protein, separated by 15% SDS-PAGE, and stained with
Coomassie blue. Lane 1, His6-FliC-VK210; lane 2, His6-FliC-VK247; lane 3, His6-
FliC-P. vivax-like; lane 4, His6-FliC-All-CS-epitopes; lane 5, native FliC. (B) Re-
combinant proteins separated by SDS-PAGEwere probedwith an anti-His6MAb.
Lane 1, native FliC; lane 2, His6-FliC-VK210; lane 3, His6-FliC-VK247; lane 4,
His6-FliC-P. vivax-like; lane 5, His6-FliC-All-CS-epitopes. (C) Recombinant pro-
teins separated by SDS-PAGEwere probed with anMAb against the VK247 CSP.
Lanes 1 to 5 contain the same samples as those described in panel B.
FIG 1 Schematic representation of the recombinant proteins used in the pres-
ent study.
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strong adjuvant. Initially, mice were immunized with the recom-
binant fusion protein His6-FliC-All-CS-epitopes alone or in com-
bination with either CFA/IFA or poly(I·C). Following the admin-
istration of 3 doses, we found that the antibody titers to all 3 allelic
forms were similar, regardless of whether the protein was used
alone or in combination with either adjuvant (Fig. 6).
Subsequently, mice were immunized with the mixture of re-
combinant fusion proteins either alone or in combination with
poly(I·C). After the second dose, the antibody titers to all 3 differ-
ent allelic forms of CSP were higher in mice immunized with the
protein mixture in combination with poly(I·C) than in mice im-
FIG 3 Immunogenicity of recombinant fusion proteins. (A) C57BL/6 mice (n  6) were immunized s.c. with 3 doses (10 g/animal/dose) of the indicated
proteins (G1 toG6) at the indicated times. The serum antibody levelsmeasured 74 days after the administration of the first dose were determined by ELISA using
plates coated with the capture agents His6-PvCSP-VK210 (B), His6-PvCSP-VK247 (C), and His6-PvCSP-P. vivax-like (D). The results are expressed as means
SD. *, the values are significantly higher than those in controls immunized with FliC alone (G1) (P 0.05, one-way ANOVA)., the value of G2 is significantly
higher than those of all other groups (G1, G5, and G6) (P 0.05, one-way ANOVA).
FIG 4 Determination of IgG subclasses in C57BL/6 mice (n 4) immunized
with 3 doses of the indicated proteins. The serum antibody titers, measured 74
days after the first dose, were determined by ELISAusing plates coatedwith the
proteins representing the homologous alleles (His6-PvCSP-VK210 [G2], His6-
PvCSP-VK247 [G3], or His6-PvCSP-P. vivax-like [G4] protein). The results
are expressed as means SD.
FIG5 TLR-5/MyD88dependenceof the serumIgGresponse inmice immunized
with the recombinant fusionproteinHis6-FliC-VK210. (A)C57BL/6mice (n6)
were immunized s.c. with 3 doses (10g/animal/dose) of recombinant protein at
the indicated time points. Serum samples were collected at the indicated time
points following the first dose, and serum antibody titers were determined by
ELISA by using plates coated with His6-PvCSP-VK210. (B) The results are ex-
pressed as means SD. *, the values are significantly lower in TLR-5 or MyD88
KOmice than in immunizedWT controls (P 0.001).
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munized with the recombinant proteins alone (Fig. 7B, C, andD).
The increase in IgG titers persisted for 180 days after the first
immunization (138 days after the last dose). The IgG1/IgG2c ra-
tios inmice immunizedwith the recombinant fusion proteinmix-
ture in the presence of poly(I·C) were 0.4 (His6-PvCSP-VK210),
1.4 (His6-PvCSP-VK247), and 0.8 (His6-PvCSP-P. vivax-like)
(data not shown). In contrast, for the animals immunizedwith the
recombinant proteins in the absence of poly(I·C), the IgG1/IgG2c
ratios were 129 (His6-PvCSP-VK210), 78 (His6-PvCSP-VK247),
and 69 (His6-PvCSP-P. vivax-like) (data not shown). These results
indicate that the immunogenicity of the recombinant fusion pro-
teinmixture can be improved by coimmunization with the TLR-3
agonist poly(I·C). Furthermore, we observed that these mice de-
veloped a balanced IgG1/IgG2c immune response in the presence
of this adjuvant, and this finding was verymuch in contrast to that
observed when the proteins were administered alone (Fig. 4).
DISCUSSION
In the present study, we evaluated the immunogenicity of recom-
binant proteins consisting of the immunodominant epitope of P.
vivax sporozoites fused to an innate immune agonist, Salmonella
Typhimurium-derived FliC. Using a mixture of 3 recombinant
proteins, IgG antibody responses to all 3 P. vivaxCSP allelic forms
were successfully elicited in mice. The immune response was spe-
cific and long lasting. These are characteristics of T-cell-depen-
dent antibody responses. However, we did not specifically inves-
tigate whether T cells were required. The antibody titers to the 3
CSP allelic variants might be further increased by coimmuniza-
tion with the TLR-3 agonist, poly(I·C).
When the effectiveness of the different strategies was com-
pared, immunization with the mixture of the 3 recombinant pro-
teins was found to be superior to immunization with a fusion
protein (His6-FliC-All-CS-epitopes) containing the epitopes de-
rived from all 3 allelic variants. Mice immunized with the His6-
FliC-All-CS-epitopes recombinant protein developed high anti-
body titers against the allelic variant P. vivax-like but mounted
significantly lower responses against the VK210 and VK247 allelic
variants. Importantly, the immune response to this recombinant
protein was not improved by coadministration of an immune
adjuvant, poly(I·C). The precise reason why this adjuvant did not
improve the antibody response is not clear. However, it does not
exclude the possibility that better results can be obtained using
other adjuvant formulations.
On the other hand, high titers of antibodies recognizing all 3 P.
vivax CSP allelic variants could be elicited by immunization of
mice with a mixture of the 3 recombinant proteins. Furthermore,
this humoral response could be improved and balanced by coad-
ministration of the TLR-3 agonist poly(I·C). The use of poly(I·C)
as an adjuvant is being clinically tested in humans (27).
Flagellins as carriers/adjuvants in recombinant protein con-
structs have been tested in different systems (reviewed in reference
28). Two of these recombinant fusion proteins, VAX125 and
VAX128, consisting of influenza epitope-flagellin fusions, have
been successfully used during phase I clinical trials. VAX125 and
VAX128Cwere generally well tolerated andwere immunogenic in
naive individuals. A large fraction of the vaccinated individuals
developed titers of neutralizing antibodies, which is consistent
with seroprotection (28, 29). These findings suggest that these
vaccine formulations may confer a degree of protection during
pandemic influenza.
While we used FliC, the studies described above used FlijB
flagellin. The difference between them is restricted to the hyper-
variable domain. No formal comparison of both proteins as an
adjuvant/carrier has been published to date. However, a compar-
isonmade in themousemodel yielded comparable results (L. C. S.
Ferreira, unpublished data).
Similar to VAX125 and VAX128C, our recombinant fusion
proteins were immunogenic even in the absence of conventional
adjuvants.We found that themain adjuvant activity wasmediated
by the ability of FliC to activate the TLR-5/MyD88 pathway, as
TLR-5 and MyD88 KO mice each displayed a significantly im-
paired immune response after vaccination. A contribution of con-
taminating bacterial lipopolysaccharide (LPS) to the observed im-
munogenicity of our formulations seems unlikely, considering
that the response in TLR-4 KO mice was similar to that in WT
mice.
The importance of antibodies targeted to the repeat domain of
CSP for immunity against the malaria sporozoites has been
known for a long time. The first MAbs specific to the CSP of
Plasmodium berghei passively transferred protection against the
experimental infection (30). These initial findings have been re-
produced in several species of Plasmodium, including P. vivax
(31). More-recent studies of phase I or II clinical assays of immu-
nization with the RTS,S/AS01E vaccine demonstrated a strong
FIG 6 Presence of strong adjuvants did not increase the immunogenicity of
the recombinant fusion proteinHis6-FliC-All-CS-epitopes. (A) C57BL/6mice
(n 6)were immunized s.c. with 3 doses (10g/animal/dose) of recombinant
protein according to the timeline in the presence or absence of the indicated
adjuvants. The serum antibody titer, 53 days after administration of the first
dose, was quantified by ELISAby using plates coatedwithHis6-PvCSP-VK210,
His6-PvCSP-VK247, or His6-PvCSP-P. vivax-like proteins. (B) Results are ex-
pressed as means  SD. *, the values are significantly higher than those in
controls injected with only poly(I·C) (P 0.001, one-way ANOVA). No sta-
tistically significant differences were found when we compared the three for-
mulations used with or without adjuvants (one-way ANOVA).
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correlation between protective immunity and the presence of an-
tibodies to the repeat domain of the P. falciparum CSP (5, 6).
Although we have clearly demonstrated the presence of P.
vivax CSP-specific antibodies targeting the repeat domain of the
different allelic variants, their function remains elusive. Prelimi-
nary immunofluorescence analyses of the VK210 and VK247
strains showed that these antibodies recognized P. vivax sporozo-
ites. However, detailed analyses need to be performed. Moreover,
the ability of these antibodies to neutralize sporozoites in vitro has
yet to be evaluated.
In contrast to P. falciparum, the development of a vaccine
against the preerythrocytic forms of P. vivax has been limited to
preclinical immunization models developed mostly in mice. A
single phase I clinical trial has been performed. Studies in mice
and a nonhuman primate examined the recombinant VMP001
protein generated in Escherichia coli. This protein contains repeat
regions derived from the VK210 allelic variant of the P. vivaxCSP.
A repeat sequence derived from the VK247 allele was also intro-
duced into the C-terminal region. This protein has been shown to
be immunogenic in different vaccine formulations and is capable
of inducing an immune response mediated by antibodies and
CD4 T cells (32–36). The specificities of the antibodies induced
by the vaccine VMP001 were not investigated by binding inhibi-
tion experiments. While in our case the immune responses are
focused on the repeat region, animals immunized with VMP001
reacted stronglywith theC-terminal region (32, 36). Interestingly,
VMP001 induced partial cross-protective immunity in mice chal-
lenged with P. berghei sporozoites (37). The region(s) of the
PvCSP that elicited this cross-protective immune response re-
mains unknown.
Studies performed in parallel used long recombinant P. vivax
CSP-derived peptides to develop a synthetic malaria vaccine (38).
Peptides representing CSP N- or C-terminal portions or the
amino acid repetitions (allele VK210) have been tested in phase I
clinical trials. This vaccine formulation, which contains the adju-
vant Montanide ISA 720, was safe and well tolerated following
administration by the intramuscular route. Vaccinated individu-
als developed antibodies that targeted 3 different epitopes of the P.
vivax CSP, and gamma interferon (IFN-)-producing cells were
observed (39).
In summary, our findings extend the understanding of the use
of Salmonella flagellin as an adjuvant and antigen carrier in vac-
cine formulations in general. More specifically, we generated re-
combinant fusion proteins consisting of fusions of different P.
vivax CSP allelic variants with flagellin and showed that a formu-
lation consisting of the mixture of these 3 allelic variant-flagellin
fusions, administered in the presence of the adjuvant poly(I·C), is
sufficient to induce strong and long-lasting anti-CSP immunity in
mice. As both flagellin and poly(I·C) have been considered to be
promising adjuvants in human trials, this formulation might be a
potentially new P. vivax vaccine candidate with broad coverage.
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FIG 7 Kinetics of the IgG immune response in C57BL/6 mice immunized with a mixture of 3 recombinant fusion proteins administered with or without the
TLR-3 agonist poly(I·C). (A) Groups ofmice (n 6) were immunized s.c. with 3 doses (1g/animal/dose) of amixture of recombinant proteins at the indicated
time points in the presence or absence of the indicated adjuvants. Serum samples were collected at different time points until day 184 following the first dose, and
serum anti-CSP antibodies were detected by ELISA using plates coatedwithHis6-PvCSP-VK210 (B),His6-PvCSP-VK247 (C), andHis6-PvCSP-P. vivax-like (D).
The results are expressed asmeans SD. *, the values are significantly higher inmice immunized with recombinant proteinmixture in the presence of poly(I·C)
than in mice injected with the mixture alone (P 0.05 in all cases).
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